Stock Watch: Some Turbulence As Novo And Lilly Report Results

Investors Should Value Birds In The Hand Above Fledglings In The Bush

 
• By Andy Smith
  
Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business